admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics...

Psychedelics Weekly – Wonderland Controversy and Colorado Proposition 122

Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of...

PT372 – The Heroic Hearts Project: Veterans and The Impact of...

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Healthline – Mental Health Breakthrough: The Therapeutic Benefits of Psychedelics

PsychCentral – All About Psychedelic Therapy

PsychCentral – Microdosing Psychedelics Linked to Lower Anxiety, Depression, Stress

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business...

1...105106107...218 Page 106 of 218

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin

Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics...

Psychedelics Weekly – Wonderland Controversy and Colorado Proposition 122

Psychedelics Weekly – Wonderland Controversy and Colorado Proposition 122

Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of...

PT372 – The Heroic Hearts Project: Veterans and The Impact of...

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Healthline – Mental Health Breakthrough: The Therapeutic Benefits of Psychedelics

PsychCentral – All About Psychedelic Therapy

PsychCentral – Microdosing Psychedelics Linked to Lower Anxiety, Depression, Stress

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business...

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY